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Midterm Comparison of Open Versus Endovascular
Repair of Pararenal Aneurysms
Raghuveer Vallabhaneni, Francis Caputo, Yazan Duwayri,
Brian G. Rubin, Patrick J. Geraghty, Kathleen G. Raman,
John A. Curci, Robert W. Thompson, Gregorio A. Sicard,
Luis A. Sanchez. Washington University School of Medi-
cine, Saint Louis, MO
Objectives: The traditional treatment of pararenal an-
eurysms has been open repair.We compared our experience
of open(ORPA) & endovascular(ERPA)repair of pararenal
aneurysms using available devices.
Methods: Retrospective review of all pararenal aneu-
rysms repaired at our institution between 1/05-5/10 was
performed. Patients with aortic necks10mm for ERPAs
or had suprarenal clamping for ORPAs were reviewed. All
ERPA patients were not considered suitable for ORPA.
SVS comorbidity scores were calculated. Death,complica-
tions & secondary interventions were primary endpoints.
Variable
Open Repair of
Pararenal
Aneurysm
Repair
(ORPA)
Endovascular
Repair of
Pararenal
Aneurysm
Repair
(ERPA) p-value
Male (%) 68.40% 86.10% p0.03
Age (years) 70  8.1 74.4  8.8
SVS combined
medical
comorbidity
severity score
0.86  0.4
(0.3-2.2)
1.27  .6
(0.6-2.5)
p0.001
Estimated blood loss
(mL)
3436  3519 370  46 p0.001
LOS (days) 13.23  8.4 7.5  11.8 p0.001
ICU LOS (days) 7.4  9.3 0.9  0.4 p0.001
In-hospital mortality 10.5% (4/38) 5.71% (2/35) p0.064
Secondary
Interventions
7.9% (3/38) 8.57% (3/35) p0.747
Cardiac
complications
34.2% (13/38) 17.1% (6/35) p0.162
Renal Complications 31.6% (12/38) 20% (7/35) p0.389
Vascular
Complications
7.9% (3/38) 8.57% (3/35) p0.747
Pulmonary
Complications
36.8% (14/38) 14.3% (5/35) p0.055
Infectious
Complications
36.8% (14/38) 14.3% (5/35) p0.055
Wound
Complications
13.2% (5/38) 2.8% (1/35) p0.234
Results: 35 ERPAs & 38 ORPAs were performed. Of
the 35 ERPAs there were 26 modified Cook Zenith de-
vices,3 TX2 devices,and 3 RENU devices. Three patients
had planned renal arteries covered to get adequate proximal
seal. Modifications to devices included scallops,fenestra-
tions,or combinations of both to accomodate the patients
anatomy. Perioperative variables,complications & out-
comes are shown in the table. ERPA patients were signifi-
cantly older & sicker (p.001), & trended towards lower
in-hospital mortality,pulmonary & infectious complica-
tions (p0.055-0.064). Kaplan-Meier survival log rank
analysis showed no difference inmortality at amean survival
time of 57.1 months (ORPA) & 45.8 months (ERPA).
Conclusions: ERPA can be performed in high opera-
tive risk patients with equivalent outcomes to ORPA using
existing technologies if the anatomy allows it. Commer-
cially available fenestrated/branched devices will likely im-
prove the outcomes in this population.
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PS10.
Non-Graft Complications after Retroperitoneal vs
Transabdominal Open Abdominal Aortic Aneurysm
Repair
Carlos A. Rueda, Clifford J. Buckley, Ruth L. Bush,
Thomas Warren, Christopher J. Marrocco, Marvin D. At-
kins, William T. Bohannon. Surgery, Scott and White Me-
morial Hospital, Temple, TX
Objectives: Evaluate non-graft complications after
open abdominal aortic aneurysm (AAA) repair including
small bowel obstruction, hernia, chronic renal failure,
infection.
Methods: Retrospective review of prospectively
maintained aneurysm database for all open AAA. Chart
evaluation of patients who had non-graft related compli-
cations at 6 months, 12 months, 3 and 5 years post-
operative. Complications related to the surgery included
small bowel obstruction, hernia, chronic renal failure and
infection. Two groups were identified and compared
based on repair technique: retroperitoneal and
transabdominal.
Results: There were a total of 395 consecutive open
AAA repairs. There were 190 retroperitoneal repairs and
205 transabdominal repairs during the 10 year period re-
viewed. Patients who had chronic complications from the
retroperitoneal repair were 75(39%) and patients who had
chronic complications from the transabdominal repair were
115(56%). Small bowel obstruction and hernia were more
common among patients who underwent transabdominal
AAA repair.
Conclusions: Retroperitoneal repair of AAA had less
non-graft related complications than transabdominal
repair.
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Use of CO2 Angiography for Complex Endovascular
Aneurysm Repair
Jane E. Cross, Dominic Simring, Luke Morgan Rowe,
Krassi Ivancev, Peter Harris, Toby Richards. Multidisci-
plinary Endovascular Team, University College Hospital,
London, United Kingdom
Objectives: Complex EVAR involving fenestrated and
branched endografts, is associated with significant post
operative complications. Increased use of iodinated con-
trast medium is associated with post operative contrast
medium induced renal dysfunction and renal failure. We
describe the use of CO2 as the primary contrast agent in
patients undergoing complex EVAR.
Methods: Two cohorts of patients undergoing fenes-
trated and branched EVAR were compared at a regional
vascular unit. 68 complex endografts were implanted be-
tween 2008 and 2010; 41 procedures were completed with
iodinated contrast media (group 1) and 27 utilised CO2 as
the primary contrast agent (group 2). Endpoints assessed
were need for renal replacement therapy or renal impair-
ment, defined as increase in creatinine of 25%.
Results: Baseline renal function was similar in each
group (creatinine group 1 median96; group 2 me-
dian102, (P0.21)). There was a significant difference in
the median change in post op creatinine (28.5 in group 1
compared to 9.5 in group 2 (P0.048)). However, there
was no significant difference in postoperative renal dys-
function (13/41 in group 1 and 8/27 in group 2
(P0.79)) or need for temporary renal support (7/41 in
group 1 and 3/27 in group 2 (P0.72). No patients
required permanent dialysis. Median volume of iodin-
ated contrast used fell from 226.25ml to 75ml (p0.43).
There was no difference between the groups in fluoros-
copy time or radiation dose.
Conclusions: Renal impairment is a common post-
operative complication amongst patients undergoing
complex EVAR, although its aetiology is multi-factorial.
CO2 angiography can be successfully used for complex
EVAR and its use may reduce the volume of iodinated
contrast used as well as lower post operative creatinine
levels.
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Contemporary Outcomes following Endovascular ver-
sus Open Repair of Abdominal Aortic Aneurysm
Prateek K. Gupta1, Bala Natarajan1, Himani Gupta1, Xiang
Fang1, Marcus Balters1, Jason M. Johanning2, Thomas G.
Lynch2, R. Armour Forse1, G. Matthew Longo2, Jason
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Objectives: The choice between endovascular (EVAR)
and open repair (OAR) to treat abdominal aortic aneu-
rysm (AAA) is frequently dependent on periprocedural
morbidity and mortality. Previous randomized clinical
trials have demonstrated better short-term outcomes
with EVAR. The objective of this study was to report the
contemporary 30-day morbidity and mortality of AAA
repair in the United States population comparing EVAR
and OAR.
Methods: Patients who underwent infrarenal AAA
repair were identified from the 2007-09 National
Surgical Quality Improvement Program - a multicenter
(more than 180 hospitals), prospective database. Univar-
iate and multiple logistic regression analyses were
performed.
Results: Of total 10,251 patients, 72% underwent
EVAR. Patients undergoing EVAR were more commonly
males (83.3% vs 74.4%), octogenarians (29.3% vs 16.7%),
and had a higher percentage of iliacs/femorals as attach-
ment site (92.5% vs 43.5%). They had less intraoperative
transfusion (median 0 vs 2 units), operative time (141 vs
211 minutes), hospital length of stay (median 2 vs 7 days),
and return to operating room (4.2% vs 8.0%). On univariate
analysis, 30-day major morbidity and mortality were lower
for EVAR (8.9% vs 24.7% and 1.2% vs 3.3%, respectively;
p0.0001 for both). After controlling for 65 comorbidi-
ties and procedural characteristics on multivariate analy-
sis, OAR was associated with higher postoperative major
morbidity (OR 1.8; 95%CI- 1.5 to 2.0; p0.0001;
c-statistic: 0.73); however, a significant difference was
not seen between OAR and EVAR for postoperative
mortality (OR 1.4; 95%CI - 0.99 to 1.99; p0.06;
c-statistic 0.81).
Conclusions:Contemporary outcomes following AAA
repair in the United States continue to be excellent. After
controlling for other factors, EVAR and OAR procedures
have similar perioperative mortality rates. OAR was, how-
ever, independently associated with 1.8 times higher peri-
operative morbidity. These data demonstrate that elective
EVAR has short-term morbidity benefits compared with
OAR.
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